Investigation Report on China Urokinase Market 2010-2019
Description
As a serine protease, urokinase is isolated from human urine or cultivated in kidneys. And it consists of LMW-tcu-PA and HMW-tcu-PA.
Activation of urokinase triggers a proteolysis cascade that participates in thrombolysis degradation. Urokinase not only immediately removes clot but also enhances the activity of ADP enzyme so as to inhibit the platelet aggregation and prevent thrombolysis. Activity of plasmin is improved when urokinase is given in the form of intravenous drip and falls back to normal level several hours later. As a traditional thrombolytic drug, urokinase is widely used in treating such thrombotic diseases as acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombus and deep vein thrombosis.
With aging population and unreasonable eating habit, the incidence of thrombotic disease has gone up, which promotes the demand for urokinase. According to CRI’s market survey, the annual sales value of urokinase rose from CNY 18.20 million in 2010 to CNY 28.95 million in 2014 with CAGR during this period reaching 12.30%. NDPHARM had the largest market share of about 48.5% for sales value in 2014.
The market size of urokinase is expected to keep growing in the next few years in China.
Readers can get at least the following information through this report:
As a serine protease, urokinase is isolated from human urine or cultivated in kidneys. And it consists of LMW-tcu-PA and HMW-tcu-PA.
Activation of urokinase triggers a proteolysis cascade that participates in thrombolysis degradation. Urokinase not only immediately removes clot but also enhances the activity of ADP enzyme so as to inhibit the platelet aggregation and prevent thrombolysis. Activity of plasmin is improved when urokinase is given in the form of intravenous drip and falls back to normal level several hours later. As a traditional thrombolytic drug, urokinase is widely used in treating such thrombotic diseases as acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombus and deep vein thrombosis.
With aging population and unreasonable eating habit, the incidence of thrombotic disease has gone up, which promotes the demand for urokinase. According to CRI’s market survey, the annual sales value of urokinase rose from CNY 18.20 million in 2010 to CNY 28.95 million in 2014 with CAGR during this period reaching 12.30%. NDPHARM had the largest market share of about 48.5% for sales value in 2014.
The market size of urokinase is expected to keep growing in the next few years in China.
Readers can get at least the following information through this report:
- market size of urokinase in China
- competitive landscape of urokinase market in China
- price of urokinase made by different enterprises in China
- market outlook of urokinase in China
- manufacturers of antithrombotic agents
- investors/research institutions interested in Chinese medicine market
1 RELATED CONCEPTS OF UROKINASE
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF UROKINASE IN CHINA
2.1 Patent and Approval Information of Urokinase in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON UROKINASE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR UROKINASE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF UROKINASE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF UROKINASE IN CHINESE HOSPITALS IN 2014
6.1 Livzon Pharmaceutical Group Co., Ltd
6.2 NDPHARM
6.3 Tianjin Biochem Pharmaceutical Co., Ltd
6.4 PKU High-Tech Huatai Pharmaceutica
6.5 Liaoning Weixing Pharmaceutical Co., Ltd
7 MAJOR MANUFACTURERS OF UROKINASE IN CHINESE MARKET, 2010-2014
7.1 NDPHARM
7.2 Livzon Pharmaceutical Group Co., Ltd
7.3 Tianjin Biochem Pharmaceutical Co., Ltd
7.4 PKU High-Tech Huatai Pharmaceutica
7.5 Liaoning Weixing Pharmaceutical Co., Ltd
8 MARKET OUTLOOK OF UROKINASE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Information of Urokinase in China
Chart Approval Information of Urokinase in China
Chart Sales Status of Urokinase in China
Chart Sales Value of Urokinase in China, 2010-2014
Chart Sales Value of Urokinase in Some Regions in China, 2010-2014
Chart Sales Volume of Urokinase in China, 2010-2014
Chart Sales Volume of Urokinase in Some Regions in China, 2010-2014
Chart Market Share of TOP5 Urokinase Manufacturers for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Urokinase Made by NDPHARM in China, 2010-2014
Chart Sales Value and Market Share of Urokinase Made by Livzon Pharmaceutical Group Co., Ltd in China, 2010-2014
Chart Sales Value and Market Share of Urokinase Made by Tianjin Biochem in China, 2010-2014
Chart Price of Urokinase Made by Livzon Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
Chart Price of Urokinase Made by NDPHARM in Some Chinese Cities in 2014
Chart Price of Urokinase Made by Tianjin Biochem Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Urokinase Made by PKU High-Tech Huatai in Some Chinese Cities in 2014
Chart Price of Urokinase Made by Liaoning Weixing in Some Chinese Cities in 2014
COMPANIES MENTIONED
NDPHARM; Livzon Pharmaceutical Group Co., Ltd; Tianjin Biochem Pharmaceutical Co., Ltd; PKU High-Tech Huatai Pharmaceutica; Liaoning Weixing Pharmaceutical Co., Ltd
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF UROKINASE IN CHINA
2.1 Patent and Approval Information of Urokinase in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON UROKINASE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR UROKINASE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF UROKINASE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF UROKINASE IN CHINESE HOSPITALS IN 2014
6.1 Livzon Pharmaceutical Group Co., Ltd
6.2 NDPHARM
6.3 Tianjin Biochem Pharmaceutical Co., Ltd
6.4 PKU High-Tech Huatai Pharmaceutica
6.5 Liaoning Weixing Pharmaceutical Co., Ltd
7 MAJOR MANUFACTURERS OF UROKINASE IN CHINESE MARKET, 2010-2014
7.1 NDPHARM
7.2 Livzon Pharmaceutical Group Co., Ltd
7.3 Tianjin Biochem Pharmaceutical Co., Ltd
7.4 PKU High-Tech Huatai Pharmaceutica
7.5 Liaoning Weixing Pharmaceutical Co., Ltd
8 MARKET OUTLOOK OF UROKINASE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Information of Urokinase in China
Chart Approval Information of Urokinase in China
Chart Sales Status of Urokinase in China
Chart Sales Value of Urokinase in China, 2010-2014
Chart Sales Value of Urokinase in Some Regions in China, 2010-2014
Chart Sales Volume of Urokinase in China, 2010-2014
Chart Sales Volume of Urokinase in Some Regions in China, 2010-2014
Chart Market Share of TOP5 Urokinase Manufacturers for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Urokinase Made by NDPHARM in China, 2010-2014
Chart Sales Value and Market Share of Urokinase Made by Livzon Pharmaceutical Group Co., Ltd in China, 2010-2014
Chart Sales Value and Market Share of Urokinase Made by Tianjin Biochem in China, 2010-2014
Chart Price of Urokinase Made by Livzon Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
Chart Price of Urokinase Made by NDPHARM in Some Chinese Cities in 2014
Chart Price of Urokinase Made by Tianjin Biochem Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Urokinase Made by PKU High-Tech Huatai in Some Chinese Cities in 2014
Chart Price of Urokinase Made by Liaoning Weixing in Some Chinese Cities in 2014
COMPANIES MENTIONED
NDPHARM; Livzon Pharmaceutical Group Co., Ltd; Tianjin Biochem Pharmaceutical Co., Ltd; PKU High-Tech Huatai Pharmaceutica; Liaoning Weixing Pharmaceutical Co., Ltd
